TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00151047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT03127826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Risk Stratified Care
Description: Physical therapists providing care will all have attended live training in PIPT principles and be involved in monthly continuing education on these principles. The use of specific principles is guided by the patient's risk stratification (as determined by the STarT Back Tool).~Medium Risk:~- Reassurance will be provided to address specific concerns related to their LBP and implications on work~High Risk:~- Physical therapy will be psychologically augmented with the assessment of biopsychosocial risk factors and the adoption of cognitive behavioral principles that explore patient concerns and address unhelpful beliefs and behaviors, including tailored education (e.g., stress management and pain neuroscience), graded exercise, \& graded exposure
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study: NCT03127826

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care at the general practitioner's discretion
Study: NCT00630149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Alimta)
Description: 500 mg/m2 in Cycle 1, every 3 weeks, with folic acid and vitamin B12 supplementation.
Study: NCT03895957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy VR Mind+
Description: Virtual Reality Exposure Self-Therapy led by a participant

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy VR Mind
Description: Treatment with Virtual Reality Exposure Therapy led by a therapist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Standard treatment for social phobia led by a therapist
Study: NCT03955757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Boot Camp Translation
Description: Communities in the intervention arm will participate in the Boot Camp translation process, where stakeholders will come together to develop and implement locally relevant materials to promote adolescent vaccination.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No intervention. Communities will continue to behave as usual.
Study: NCT03348423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEX-IN
Description: IN Dexmedetomidine + IV placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: IN Placebo + IV Fentanyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IN Placebo + IV Placebo
Study: NCT02803398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression bandages application and interface pressure measurements
Description: Bandages, which are applied in a spiral pattern on the leg, are composed of Biflex 16 (Thuasne) and/or Rosidal K (Lohmann \& Rauscher).
Study: NCT02036918

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymph Node Biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Biopsy
Study: NCT02208440

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Best Repair of torn Rotator Cuff

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InSpace™ system
Study: NCT02864485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: live donor liver transplantation
Description: live donor liver transplantation
Study: NCT01143805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasocitinib 10 mg oral tablet
Description: Treatment A: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of an oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasocitinib 10 mg IV Infusion
Description: Treatment B: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of a 30 minute intravenous infusion
Study: NCT02250833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828
Description: Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
Study: NCT00430118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Study: NCT02250833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: - Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-amlodipine
Description: - S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study: NCT01687647

Intervention type: OTHER
Group type: OTHER
Intervention: low-dose CT-scan AND induced sputum sample AND blood test
Description: All subjects will receive a low-dose CT-scan, a blood test (ancillary study) and provide an induced sputum
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study: NCT06094985

Intervention type: GENETIC
Intervention: DNA exome sequencing of tumor and blood
Description: A piece from tumor and a blood sample will be collected during surgery. DNA will be extracted and presence of tumor specific mutations/aberrations will be analysed with a DNA exome seq panel. Presence of identified markers will be followed in blood samples with the same panel and these blood samples will be collected in routine follow-up during the first two years. Presence of markers over time in blood will be correlated to outcomes 1-5.
Study: NCT01891526

Intervention type: DRUG
Intervention: 9-cis-retinoic acid
Description: Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure

Intervention type: DRUG
Intervention: 9-cis-retinoic acid
Description: Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure
Study: NCT04560244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1701
Description: PD-L1 / TGF-β RII double antibody
Study: NCT00641316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AtraumaticTeeth Extraction
Description: Teeth extraction alone, allowed to heal for 2 months followed by implant therapy to the sites

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic Teeth Extraction/Grafted Extraction Sockets
Description: Teeth extraction/post-extraction socket grafting with Freeze-Dried Bone Allograft (FDBA) mixed with Tri-Calcium Phosphate(TCP) allowed to heal for 2 months followed by dental implant therapy to the sites
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide
Study: NCT00641316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic Teeth Extraction/Grafted Extraction Sockets
Description: Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Autologous Platelet-Rich Plasma (PRP) allowed to heal for 2 months followed by dental implant therapy to the sites

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic Teeth Extraction/Grafted Extraction Sockets
Description: Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Platelet-Derived Growth Factors (PDGF) allowed to heal for 2 months followed by dental implant therapy to the sites
Study: NCT00430118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study: NCT01082822

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell sheet pellets and cell sheet fragment
Description: the denuded root surface area was calculated to determine the size of the transplanted cell sheet in the of proportion of the 2cm X 2cm cell sheet to the 1cm X 1cm denuded area

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: cell sheet pellets and cell sheet fragment
Description: the denuded root surface area was calculated to determine the size of the transplanted cell sheet in the of proportion of the 2cm X 2cm cell sheet to the 1cm X 1cm denuded area

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell sheet pellets and cell sheet fragment
Description: the denuded root surface area was calculated to determine the size of the transplanted cell sheet in the of proportion of the 2cm X 2cm cell sheet to the 1cm X 1cm denuded area
Study: NCT01740505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timing and Coordination
Description: This intervention is based on progressively difficult stepping and walking patterns that promote the timing and coordination of stepping within the gait cycle. Small-group 60-minute classes twice weekly for 12 weeks.
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Study: NCT01740505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Walking
Description: Outdoor walking with progressive increases in exercise intensity. Small-group 60-minute classes twice weekly for 12 weeks.
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study: NCT03941925

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic fructans
Description: Prebiotic group receiving the prebiotic fructans in two doses during the 4-week intervention period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-prebiotic maltodextrin
Description: Placebo group receiving the non-prebiotic maltodextrin in two doses during the 4-week intervention period.
Study: NCT02330380

Intervention type: DRUG
Intervention: Methotrexate
Description: Subjects will receive Methotrexate as detailed in the Group description.

Intervention type: DRUG
Intervention: Ustekinumab
Description: Subjects will receive Ustekinumab as detailed in the Group description.

Intervention type: DRUG
Intervention: Etanercept
Description: Subjects will receive Etanercept as detailed in the Group description.

Intervention type: DRUG
Intervention: Adalimumab
Description: Subjects will receive Adalimumab as detailed in the Group description.
Study: NCT00430118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study: NCT02330380

Intervention type: DRUG
Intervention: Acitretin
Description: Subjects will receive Acitretin as detailed in the Group description.

Intervention type: OTHER
Intervention: UVB Excimer Laser
Description: Subjects will receive UVB Excimer Laser therapy as detailed in the Group description.

Intervention type: OTHER
Intervention: Narrowband UVB
Description: Subjects will receive Narrowband UVB as detailed in the Group description.
Study: NCT01822483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium
Description: The conversion will be performed abruptly for all patients. Mycophenolate mofetil will be discontinued one day before the day of conversion (Day 1). Mycophenolate sodium will be introduced on day 1 with equivalent doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil dose will be maintained or adjusted to keep 30 to 60 mg\*h ml-1.
Study: NCT00481676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab 75-375 mg
Description: Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg of omalizumab upon reconstitution with 1.4 ml sterile water for injection.
Study: NCT02086747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 100 ml iv, 4 times a day for 72 hours
Study: NCT00481676

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to omalizumab
Description: Placebo to omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg placebo to omalizumab upon reconstitution with 1.4 ml sterile water for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine
Description: All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study: NCT02086747

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic
Description: 100 ml iv, 4 times a day for 72 hours
Study: NCT01792635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: PF-05175157 will be administered at 200 mg twice a day for 43 days.
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Study: NCT01792635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matched to PF-05175157 will be administered twice a day for 43 days.
Study: NCT01516996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel and cisplatin
Description: * The neoadjuvant consists of docetaxel 75mg/m2 day 1 and cisplatin 75mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.~* CCRT: cisplatin 75mg/m2 is administered on day 1 of week 7,10 and 13 on current with RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and cisplatin
Description: * The neoadjuvant consists of docetaxel 75mg/m2 day 1 and cisplatin 75mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.~* CCRT: cisplatin 75mg/m2 is administered on day 1 of week 7,10 and 13 on current with RT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: IMRT is administered with chemotherapy from week 7 to week 13~* GTV（primary tumor）：68-70Gy/35\~38 F，once a day, 5 times per week~* CTV（Clinical target）：56-66Gy/30\~36f，once a day, 5 times per week~* GTV-ln（positive neck region）：66-70Gy/33\~36 F，once a day, 5 times per week~* CTV-ln（negative neck region）：50-54Gy/28\~30F, once a day, 5 times

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT is administered with chemotherapy from week 7 to week 13~* GTV（primary tumor）：68-70Gy/35\~38 F，once a day, 5 times per week~* CTV（Clinical target）：56-66Gy/30\~36f，once a day, 5 times per week~* GTV-ln（positive neck region）：66-70Gy/33\~36 F，once a day, 5 times per week~* CTV-ln（negative neck region）：50-54Gy/28\~30F, once a day, 5 times
Study: NCT00481676

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clemastine
Description: All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
Study: NCT01703156

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stress Test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Stress Test
Study: NCT01516996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab was administered 200 mg IV over 1 hour on day 1,once a week, for 13\~14 weeks
Study: NCT01667679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet
Study: NCT02017223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knowme Device Wear
Study: NCT01740505

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching and Relaxation
Description: Full-body stretching, range-of-motion exercises, and relaxation techniques. No specific gait training. Small-group 60-minute classes twice weekly for 12 weeks.
Study: NCT01203852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol 50 mg twice daily titrated to 100 mg twice daily~Note: due to discontinuation of the manufacture of chlorthalidone 15 mg, effective Jan 1, 2013; the starting dose of chlorthalidone will be 25 mg 4 times per week (Mon, Wed, Thur, Sat) with subsequent titration to 25 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Description: Chlorthalidone 25 mg 4 times per week titrated to 25 mg daily
Study: NCT02756988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987704)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number: X71-109)
Study: NCT00929669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pasireotide LAR
Description: pasireotide LAR 80 mg IM once a month
Study: NCT02984345

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mycoprotein beverage
Description: Mycoprotein protein beverage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Milk protein beverage
Description: Milk protein beverage
Study: NCT02368392

Intervention type: OTHER
Intervention: Exposure for cardiac arrests
Description: There is no particular intervention. This study merely observes the occurrence of cardiac arrests

Intervention type: OTHER
Intervention: Exposure for cardiac arrests
Description: There is no particular intervention. This study merely observes the occurrence of cardiac arrests
Study: NCT01671943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ice-Sense3TM
Description: Ice-Sense Cryoprobe
Study: NCT01096628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic + Exercise
Description: Treatment will include eight to 16 treatments provided over the 12-week period. Each treatment visit will last from 10-20 minutes and consist of manual spinal manipulation and mobilization. Light soft tissue techniques (i.e., active and passive muscle stretching, hot and cold packs, and ischemic compression of tender points) will be used as indicated to facilitate the manual therapy.~Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise.
Study: NCT03706924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500FDC
Description: A fixed-dose combination of three active substances: tenofovir 300 mg + elsulfavirine 20 mg + emtricitabine 200 mg, film-coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elpida®
Description: Elpida®, capsules, elsulfavirine 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada®
Description: Truvada® (tenofovir 300 mg / emtricitabine 200 mg), film-coated tablets
Study: NCT03896893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin antisepsis
Description: 1% aqueous chlorhexidine gluconate
Study: NCT04465864

Intervention type: DRUG
Group type: OTHER
Intervention: Intracanalicular Dexamethasone, 0.4 mg insert
Description: Intracanalicular Dexamethasone, 0.4 mg insert four days (+/- 1 day) prior to surgery or inserted the day of surgery.

Intervention type: DRUG
Group type: OTHER
Intervention: Intracanalicular Dexamethasone, 0.4 mg insert
Description: Intracanalicular Dexamethasone, 0.4 mg insert four days (+/- 1 day) prior to surgery or inserted the day of surgery.